Allena Pharmaceuticals

Oral enzymes for kidney disease

Newton, Massachusetts, US

Allena Pharmaceuticals develops non-systemic protein therapeutics for metabolic and orphan diseases.

Shareable draft

Check out Allena Pharmaceuticals on @MedStartr Today Allena Pharmaceuticals develops non-systemic protein therapeutics for metabolic and orphan diseases. #OrphanDiseases #KidneyStones #Hyperoxaluria #MetabolicSyndrome #MentalBehavioralHealth #MetabolicDiseases #DrugDiscoveryDevelopment #MedMo #MedStartrVentures

https://www.medstartr.ai/s/iEZu1PmKe-M

Note, this image was autogenerated by Syggy based on what we know about the company. It is not an official company publication.

Get Involved in Allena Pharmaceuticals

1 engagement

How We Help

Problem Statement

Patients with rare and severe metabolic and kidney disorders suffer from the excess accumulation of metabolites like oxalate and urate, which can cause kidney stones, kidney damage, chronic kidney disease (CKD), and end-stage renal disease.

Core Technology

Oral enzyme therapeutics

Key Differentiators

First-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders

Clinical Focus

Nephrology; Metabolic Disorders

Company Info

Total Funding: Only accessible to MedStartr community members. Join now
Only accessible to MedStartr community members.
Join now
Website: allenapharma.com

Disease Areas

Orphan Diseases Kidney Stones Hyperoxaluria Metabolic Syndrome Mental Health Metabolic Diseases

Technologies

Oral Enzyme TherapeuticsBiopharmaceutical

Clinical & IP

🔬

Clinical Validation

Lead candidate reloxaliase in Phase 3 (URIROX-2) with positive Phase 2 data and FDA accelerated approval pathway alignment. ALLN-346 has FDA Fast Track designation for gout-CKD indication. Demonstrated efficacy in reducing urinary oxalate and managing hyperuricemia.

🌐Website

MedStartr Engagement Score

The MedStartr Index is a reflection of how the crowds that come to MedStartr everyday to find healthcare innovations reacted. Calculated by our AI agent Fyggy based on algorithms we have been building since 2012 and over 100 different factors, the math is proprietary and complex. Suffice to say, it has been found to be highly correlative with early stage company growth. What you see here is the public version. To learn more or to get deeper access to our predictive data on startup success for your fund or company, click here.

Comments

Comments from new members are shown once the company's team has approved them. Please follow the community rules.

Be the first to comment.

What do you think of Allena Pharmaceuticals?

A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.

Clinical Benefit Potential

The potential for a project to have a large and significant impact on medical care, treatment, or prevention.

Feasibility

The likelihood that this will provide benefit for patients / care givers and that the founders can execute on their vision and plan.

Innovativeness

The distinguishing features, concept, or technology that differentiates the entry compared to others that already exist and are in widespread use.

Fundability

The reviewers' beliefs that the idea is fundable or can make it to sustainability without outside investment.

Scalability

Some great ideas are destined to failure because they are too complex or too expensive. The reviewer should consider the likelihood that a project as explained, or perhaps with some tweaks, could possibly become a worldwide solution within a reasonable time frame.

Presentation Quality

How well the team presented the idea.

Submit anonymously — my name won't be shown to the team or on this profile

Your scores and comments are shown with your review on this company's profile.